Objectives. Development of nanoparticles (NPs) for biomedical applications, including medical imaging and drug delivery, is currently undergoing a dramatic expansion. Diverse eff ects of diff erent type NPs relating to mammalian reproductive tissues have been demonstrated. Th e objective of this study was to explore the in vitro eff ects of polymeric nanoparticle poly(ethylene glycol)-blockpolylactide methyl ether (PEG-b-PLA NPs) on functional state and viability of ovarian granulosa cells (GCs), which play an important role in maintaining ovarian function and female fertility.
Th e development of specialized nanomaterials (NMs)/nanoparticles (NPs) for use in medicine for diagnosis and treatment of many disease entities is increasing. Applications of nanotechnology-based drugs include use in biotechnology, healthcare, pharmaceuticals, drug delivery and skincare. Over the past few decades, polymeric micelles have attracted increasing attention as the carriers for various biologically active substances such as drugs, proteins and nucleic acids (De Jong and Borm 2008; Moritz and Geszke-Moritz 2015; Wang and Rempel 2015; Wang et al. 2017) . Polymeric micelles exhibited good biodegradability and biocompatibility; they off er numerous attractive features such as targeted drug delivery, sustained release or prolonged circulation half-life (Semete et al 2010; Moritz and Geszke-Moritz 2015) .
An amphiphilic block copolymer (ABC) poly(ethylene glycol)-block-poly(lactic acid) (PEG-b-PLA), a U.S. Food and Drug Administration (FDA)-approved material, has been designed as a carrier for poorly water-soluble drugs to improve their pharmacokinetics and overcome multidrug resistance (Kedar et al. 2010; Xiao et al. 2010; Shin et al. 2012; Shen et al. 2015) . Polymeric NPs, including PEG-b-PLA, represent one of the most promising approaches for CNS drug delivery, due to their ability to cross the blood brain barrier (BBB) (Tosi et al. 2008; Patel et al. 2012) . PEGylated liposomal doxorubicin (PLD) has been already approved for treatment of advanced ovarian cancer patients failing fi rst-line platinumbased treatment (Ferrandina et al. 2010) .
Polyethylene glycols (PEG) have extensive medical applications, many with signifi cant relevance to gastroenterology. During polymeric NP preparation, PEG can be used as a stabilizer or applied as a linker for conjugation of targeting ligands to the surface of NPs. Th e modifi cation of drug carriers with watersoluble PEG can contribute to a signifi cant increase in the circulation half-life in vivo of as-prepared nanovehicles (Moritz and Geszke-Moritz 2015; Wang and Rempel 2015) . PEG is not known to be metabolized in humans and there are no known pharmacological actions or confi rmed toxicity resulting from the limited absorption. Pelham et al. (2008) confi rmed that orally administered PEG-3350 was minimally absorbed, rapidly excreted and primarily eliminated via faeces in healthy young and elderly subjects. However, Gajdova et al. (1993) reported that Tween 80 with PEG-350 as an active ingredient has the potential to behave as a hormone/estrogen active agent. Neonatal exposure of female rats to PEG-350 signifi cantly accelerated their sexual maturation, prolonged the estrous cycle, and induced persistent vaginal estrus.
Moreover, ovaries were without corpora lutea and had degenerative follicles (Gajdova et al. 1993) .
For safe application of NPs in biomedicine, it is crucial to exclude their potential toxic eff ects (De Jong and Borm 2008; Oberdoster 2009; Rollerova et al. 2011; Sharma et al. 2012) . Th e association between the exposure to NMs/NPs and their adverse eff ects on reproductive/neuroendocrine development and function is apparent from a number of in vivo and in vitro studies (Ema et al .2010; Campagnolo et al. 2012; Taylor et al. 2012; Lu et al. 2013) . Th e adverse eff ects of polymeric NPs have not been extensively studied and only few studies have focused on their eff ects on reproductive system to date. We have previously shown that neonatal exposure to PEG-b-PLA NPs (20, 40 mg/kg b.w.) may induce delayed adverse eff ects on hypothalamic-pituitary-ovarian axis development (accelerated onset of vaginal opening) and function [reduced number of regular estrous cycles, altered course of hypothalamic gonadotropin-releasing hormone (GnRH)-stimulated luteinizing hormone (LH) secretion, and increased progesterone serum levels] in 6-month-old female rats (Rollerova et al. 2015a ). In addition, neonatal treatment with PEG-b-PLA NPs (20 mg/kg b.w.) signifi cantly increased basal and LHRH-induced in vitro LH release from anterior pituitary cells of infantile and adult female rats (Scsukova et al. 2015) . Th e molecular mechanisms of the action of PEG-b-PLA NPs on female reproductive system are still unknown.
Granulosa cells (GCs) represent the major cell population in ovarian follicles; they play an essential role in the development of maturation of follicles, and thereby in maintaining ovarian function and female fertility. Th e growth and proliferation of GCs are one of the signifi cant signs of follicular development. To address the impact of polymeric PEG-b-PLA NPs on possible toxicity concerning the reproductive system, we examined the eff ect of PEG-b-PLA NPs and the bulk form of PEG with an average molecular weight of 300 (PEG-300) on ovarian steroidogenesis using in vitro model of primary culture of porcine GCs.
Materials and Methods
Reagents. Copolymer PEG-b-PLA[CH3O(CH2CH2O) ×(COCHCH3O)yH, PEG average Mn = 350 g/mol, PLA average Mn = 1000 g/mol, CAS 9004-74-4], poly(ethylene glycol) with an average molecular of 300 (PEG-300), tetrahydrofuran (THF; anhydrous, inhibitor free, purity ≥99.9%), medium M199, fetal bovine serum (FBS), 4-Androstene-3,17-dione (androstenedione), 8-Bromoadenosine 3´,5´-cyclic monophosphate (8Br-cAMP), 3-(4, 5)-dimethylthiazol-2, 5-diphenyltetrazolium bromide (MTT) and all other chemicals were purchased form Sigma-Aldrich (Steinheim, Germany). Forskolin was from ICN Biochemicals (Aurora, OH, U.S.A.). Antibiotic-Antimycotic solution (100x) was obtained from Biosera (Nualle, France). Porcine follicle-stimulating hormone (pFSH; USDA-pFSH-I-2, AFP-10640B) was from Dr. A.F. Parlow, NIDDK s National Hormone & Pituitary Program (Torrance, CA, U.S.A.).
Preparation and characterization of PEG-b-PLA NPs. Fresh NP micelles of PEG-b-PLA were prepared by modifi ed solvent evaporation method according to Du et al. (2009) and Shin et al. (2009) . Briefl y, copolymer PEG-b-PLA (20 mg) was dissolved in 2 ml of THF and stirred for 2 h at room temperature (RT). Under moderate stirring (100 rpm, MR Hei-Standard Heidolph, Germany), the ultrapurifi ed water (10 ml) (MiliporeMili-Q Synthesis, 18.5MΩ) was added dropwise. Two hours later, THF was evaporated under mild vacuum (rotating evaporator LABOROTA 4010-digital, Heidolph, Germany) for 1 h at 48ºC to obtain polymer micelles. Aft er THF evaporation, water was added to the suspension to obtain the fi nal PEG-b-PLA concentration of 2 mg/ml. Immediately before administration, PEG-b-PLA suspension was vortexed at the highest speed for 1 min.
Physical particle size, general state of agglomeration/aggregation and morphology of PEG-b-PLA suspension were determined by transmission electron micrography (TEM) using JEM 1200 microscope (JOEL, Tokyo, Japan) with 120 kV voltage. Zeta potential was measured by Nicomp Submicron Particle Sizer Autodilute Model 380 (Santa Barbara, CA, USA) using the electrophoretic light scattering (ELS) method. Size distribution of PEG-b-PLA was evaluated by dynamic light scattering (DLS) with a NICOMP TM 380 ZLS Particle Sizer (Santa Barbara, CA, USA) (for details see Rollerova et al. 2015a) .
Isolation and culture of GCs. Ovaries of noncycling pubertal gilts, about 90 days of age, were obtained aft er slaughter at a local abattoir. Th ey were washed several times in sterile 0.9% NaCl. GCs were aspirated by sterile syringe and needle from follicles 3-5 mm in diameter and isolated by centrifugation for 10 min at 1000 x g. Cells were then washed, resuspended in culture medium M199 (with Earle salt, 1 mM L-glutamine, and HEPES buff er) supplemented with 1% antibiotic-antimycotic solution and 10% FBS at fi nal density 1 x 10 7 cells/ml medium and cultured in 5% CO 2 incubator at 37°C. Th e density of cells was measured by a handheld automated cell counter Scepter (Millipore, Billerica, MA, USA) and cell viability was determined in a hemocytometer by trypan blue exclusion, the cell viability ranged from 80 to 90%.
Treatment of GCs for steroid hormone measurement. GCs were seeded in 24-well plates (TPP AG, Trasadingen, Switzerland) at a density 10 6 cells/well (4 wells/group/experiment), recovered for 24 h and then cultured with diff erent concentrations of PEG-b-PLA NPs (0.2-100 μg/ml) or PEG-300 (0.2-40 mg/ml) in the absence/presence of stimulators, pFSH (1 μg/ml), androstenedione (100 nM), forskolin (10 μM) or8Br-cAMP (100 μM), for diff erent time periods (24, 48, and 72 h). Control cells were treated with an equal volume of vehicle alone (ultrapurifi ed water aft er evaporation of THF). Aft er exposure to the tested agents, the culture media were collected and stored at -20 °C until assayed for radioimmunoassay. Th e experiments were repeated from three to fi ve times.
Determination of cell viability. GCs were seeded in 96-well plates (TPP AG, Trasadingen, Switzerland) at a density 10 5 cells/well (6 wells/group/experiment), recovered for 24 h and then cultured with diff erent concentrations of PEG-b-PLA NPs (1-100 μg/ml) or PEG-300 (0.2-40 mg/ml) for next 48 and 72 h. Control cells were treated with an equal volume of vehicle alone. Th e cell viability was determined by the method using a colorimetric assay with MTT. Briefl y, aft er treatment with tested agents, the culture medium was replaced with 100 μl of the fresh medium containing 0.5 mg/ml MTT and the cells were incubated for 4 h at 37°C. Th e medium was removed and replaced with 100 μl of DMSO. Th e absorbance was measured on microplate reader at 560 nm. Cell viability was expressed as the relative formazan formation in treated samples compared to control cells aft er correction for background absorbance. Th e experiments were repeated three times.
Hormone determination. Progesterone concentration in culture media was determined by commercial radioimmunoassay (RIA) test kit according to the manufacturer's instructions (Institute of Izotopes Ltd, Budapest, Hungary). Th e assay sensitivity was 0.14 ng/ml. Th e intra-assay and inter-assay CVs were <10.2% and <11.8%, respectively. Th e concentration of estradiol in culture media was measured by commercial enzyme immunoassay (EIA) test kit according to the manufacturer's instructions (MP Biomedicals, Orangeburg, NY, USA). Th e assay sensitivity was 10 pg/ml. Th e intra-assay and inter-assay CVs were <24.1% and <26.7%, respectively.
Statistical analysis. Th e data are expressed as the mean ± standard error of the mean (SEM) of 3−5 independent experiments. Statistical analysis was performed with a One-way Analysis of Variance (ANOVA) followed by Tukey-Kramer or Bonferroni multiple comparisons test. Values of p<0.05 were considered signifi cant. Sigma Plot 11.0 soft ware (Systat Soft ware, GmbH, Erkhart, Germany) was used for statistical analysis.
Results
Characterization of PEG-b-PLA NPs. TEM demonstrated spherical shape of NPs and the average primary particle size about 50 nm. Zeta potential value was 28.73±1.44 mV. Th e micelle dispersion resulted in size distribution with two main peaks of secondary particle sizes, averaged as 64.9±10.5 nm and 911.4±177.6 nm, what indicates that the PEG-b-PLA micelles were aggregated in solution. Th e PEG-b-PLA micelles were stable for 24 h at ambient temperature as monitored by TEM (for details see Rollerova et al. 2015a) .
Eff ect of PEG-b-PLA NPs on progesterone secretion. Initially, we examined time-and dose-dependent eff ects of PEG-b-PLA NPs on FSH-stimulated progesterone release by GCs (Figure 1 ). Supplementation of culture medium with FSH (1 μg/ml) stimulated progesterone secretion by GCs into the culture medium aft er 24, 48 and 72 h treatment compared to corresponding basal levels (increase by 33, 140 and 244 times, respectively; p<0.001; Figure 1 ). Aft er 24 and 48 h culture, PEG-b-PLA NPs at concentrations of 50 and 100 μg/ml decreased FSH-stimulated progesterone release when compared to control levels (p<0.001; Figure 1 ). Aft er 72 h treatment of GCs with PEG-b-PLA NPs, a signifi cant decrease in FSH-induced progesterone secretion was observed at concentrations of 5 μg/ml (p<0.01), 50 and 100 μg/ml (p<0.001) compared to FSH treatment alone (Figure 1) . At the highest tested concentration (100 μg/ml), the inhibition in progesterone release was associated with a decreased viability of GCs (decrease by 15%; p<0.001; Figure 2) . Based on the above presented results, we examined the eff ects of lower concentrations of PEG-b-PLA NPs on basal and FSH-induced progesterone release by GCs aft er 72 h culture (Figure 3) . PEG-b-PLA NPs at concentrations of 20 and 40 μg/ml induced a signifi cant decrease in basal progesterone secretion by GCs compared to controls (p<0.001; Figure 3A ). Supplementation of culture medium with FSH (1 μg/ml) signifi cantly stimulated progesterone release by GCs compared to basal levels (p<0.001; Figure 3B ). PEGb-PLA NPs signifi cantly inhibited FSH-stimulated progesterone secretion by GCs at doses of 4 μg/ml (p<0.01), 20 and 40 μg/ml (p<0.001) when compared to FSH treatment alone ( Figure 3B ).
To explore possible eff ects of PEG-b-PLA NPs on FSH-induced signaling pathway, we examined dosedependent eff ects of PEG-b-PLA NPs on forskolinand 8Br-cAMP-stimulated progesterone production by GCs aft er 72 h culture (Figure 4) . Supplementation of culture medium with forskolin (10 μM) and 8Br-cAMP (100 μM) increased progesterone secretion by GCs aft er 72 h culture (increase by 31 and 3 times, respectively; p<0.001; Figure 4) . Treatment of GCs with PEG-b-PLA NPs reduced forskolin-stimulated progesterone release by GCs at concentration of 4 μg/ml (p<0.05) and 20 μg/ml (p<0.001) compared to forskolin treatment itself (Figure 4) . PEG-b-PLA NPs had no signifi cant eff ect on 8Br-cAMP-stimulated progesterone secretion by GCs (Figure 4) . Eff ect of PEG-b-PLA NPs on estradiol secretion. Supplementation of culture medium with androstenedione (100 nM) stimulated estradiol release by GCs compared to basal levels (increase by 160 times; p<0.001; Figure 5 ). Treatment of GCs cells with PEGb-PLA NPs induced a dose-dependent reduction in androstenedione-stimulated estradiol release by GCs aft er 72 h culture ( Figure 5 ).
Eff ect of PEG-300 on progesterone secretion by GCs. We further examined the eff ects of PEG-300 on basal and FSH-induced progesterone release by GCs aft er 72 h culture (Figure 6 ). Treatment of GCs with the highest tested concentration of PEG-300 (40 mg/ml) signifi cantly decreased basal (p<0.001; Figure 6A ) as well as FSH-stimulated (p<0.001; Figure 6B) progesterone secretion by GCs compared to control levels or FSH treatment itself. Th e reduced progesterone production was associated with the decreased viability of GCs aft er 48 and 72 h culture (decrease by 60%; p<0.001; Figure 7 ).
Discussion
Nanotechnology-based drugs, nanodrugs, have been developed and tested for many diagnostic and therapeutic applications. Natural and synthetic polymers (liposomes, dextrans, PLA, PLGA, and dendrimers) have been used to prepare a wide variety of nanocarriers for delivering therapeutic and imaging agents to reduce toxicity and side eff ects associated with particular drugs. Despite a lot of merits of these NMs/NPs, their fate in biological systems and associated side eff ects on living organisms should be evaluated. Th e adverse eff ects of nanovesicles have not been extensively studied, possibly because the components of these NPs are mainly biodegradable, biocompatible and U.S. FDA-approved materials (Semete et al. 2010) . However, several recent fi ndings have reported possible harmful eff ects and unexpected toxicities associated with nanocarriers on organ systems (De Jong and Borm 2008; El-Ansary and Al-Daihan 2009; Oberdoster 2009; Sharma et al. 2012) . It has been demonstrated that NPs can pass through biological membranes (Wang et al. 2008; Rollerova et al. 2015b) ; raising fears that they can aff ect the physiology of any cell in the body.
In recent years, reproductive and developmental toxicity has increasingly become recognized as an important part of overall toxicology. Findings from the recent in vivo and in vitro studies have demonstrated that metal and metal oxide NPs can interfere with normal female reproductive functions including cytotoxic eff ects on ovarian somatic cells, impairing oogenesis and follicle maturation, and altering normal sex hormone levels (Iavicoli et al. 2013; Pottler et al. 2015; Rollerova et al. 2015b; Zhang et al. 2016) .
In the present study, primary porcine ovarian GCs in culture have been used to determine the possible adverse eff ects of polymeric PEG-b-PLA NP, designed as a carrier for poorly water-soluble drugs, on female reproductive tissue. For the fi rst time, we have examined the in vitro eff ects of PEG-b-PLA NPs (0.2-100 μg/ml) and bulk form of PEG-300 (0.2-40 mg/ml) on proliferation a steroid hormone secretion by GCs. We found that treatment of GCs with PEG-b-PLA NPs induced a signifi cant decrease in basal as well as FSH-stimulat- Incubation of GCs with PEG-300 signifi cantly inhibited basal as well as FSH-stimulated progesterone secretion above the concentration of 40 mg/ml. PEGb-PLA NPs and PEG-300 signifi cantly decreased the viability of GCs at the highest tested concentrations (100 μg/ml and 40 mg/ml, respectively) suggesting that PEG-b-PLA NPs and PEG-300 inhibited proliferation of GCs and thereby reduced secretion of steroid hormones by GCs. Using in vivo experimental model, we have previously shown that neonatal exposure female rats to PEG-b-PLA NPs (20 mg/kg b.w.) resulted in the elevated progesterone serum levels associated with a signifi cantly increased number of irregular estrous cycles and prevalence of the diestrus stage in adult animals, and an alteration of pituitary LH response to LHRH stimulation (Rollerova et al. 20015a) . FSH receptor (FSHR) when activated by its ligand FSH couple to Gαs protein, which in turn stimulates adenylyl cyclase leading to an elevation in intracellular cAMP and subsequent activation of protein kinase A (PKA). Elevation of intracellular cAMP in GCs by gonadotropins, forskolin (an adenylyl cyclase activator), or membrane-permeable 8Br-cAMP promotes steroidogenesis by increasing expression and activity of enzymes involved in steroid hormone synthesis (Jamnongjit and Hammes 2006) . To explore possible eff ects of PEG-b-PLA NPs on FSH-induced signaling pathway, we examined dose-dependent eff ects of PEG-b-PLA NPs on progesterone production by GCs stimulated by forskolin and 8Br-cAMP. PEG-b-PLA NPs reduced forskolin-stimulated, but not cAMPinduced progesterone production by GCs indicating that the tested NPs might aff ect FSH signaling at membrane level. Xiao et al. (2011) investigating the cellular uptake mechanisms of PEG-b-PLA micelles demonstrated that they fi rstly interacted with cell membrane, induced cell membrane depolarization and enhance membrane microviscosity in a dosedependent manner. Previously, we have reported that cell membrane microenvironment plays an essential role in regulation of structure-function relationship of gonadotropin receptors (Kolena et al. 1995) . Th e obtained results might indicate that understanding of interaction of NPs with cell membranes and their internalization into the cells is important in determining their diverse biological responses.
Th e present in vitro results together with our previous in vivo data indicate that polymeric PEG-b-PLA NPs might induce adverse eff ects on steroid hormone production by ovarian cells and thereby could modify reproductive functions. However, the molecular mechanisms of polymeric NPs PEG-b-PLA action remain unclear and needs further investigation.
